SC
ENTA icon

Stempoint Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Stempoint Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-75,194
Closed -$900K – 94
2025
Q3 		$900K Buy
+75,194
New +$601K 0.18% 66

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stempoint Capital's ENTA Position: Q4 2025 in Review

Stempoint Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2025, closing a stake of 75,194 shares — an estimated $900K sold.

Stempoint Capital first reported a position in ENTA in Q3 2025 and held it in 1 quarter. The position peaked at $900K in Q3 2025. 131 funds tracked by Wall St. Rank hold ENTA as of Q4 2025.

  • Stempoint Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Stempoint Capital sold 75,194 Enanta Pharmaceuticals shares in Q4 2025, an estimated $900K.
  • Stempoint Capital first reported a position in Enanta Pharmaceuticals in Q3 2025 and held it in 1 quarter.
  • Stempoint Capital's Enanta Pharmaceuticals position peaked at $900K in Q3 2025.
  • 131 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2025.

Based on Stempoint Capital's 13F filing for Q4 2025, filed 17 Feb 2026.